0001209191-16-147151.txt : 20161027 0001209191-16-147151.hdr.sgml : 20161027 20161027162858 ACCESSION NUMBER: 0001209191-16-147151 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161025 FILED AS OF DATE: 20161027 DATE AS OF CHANGE: 20161027 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MATEON THERAPEUTICS INC CENTRAL INDEX KEY: 0000908259 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 133679168 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 701 GATEWAY BLVD. STREET 2: SUITE 210 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-635-7000 MAIL ADDRESS: STREET 1: 701 GATEWAY BLVD. STREET 2: SUITE 210 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: OXIGENE INC DATE OF NAME CHANGE: 19930628 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SANDAGE BOBBY W PHD CENTRAL INDEX KEY: 0001046352 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-21990 FILM NUMBER: 161955858 MAIL ADDRESS: STREET 1: C/O 99 HAYDEN AVE STREET 2: 1 LEDGEMONT CENTER CITY: LEXINGTON STATE: MA ZIP: 02173 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2016-10-25 0 0000908259 MATEON THERAPEUTICS INC MATN 0001046352 SANDAGE BOBBY W PHD C/O MATEON THERAPEUTICS, INC. 701 GATEWAY BLVD., SUITE 210 SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Stock Option (Right to Buy) 0.58 2016-10-25 4 A 0 135612 0.00 A 2022-10-25 Common Stock 135612 135612 D Dr. Sandage was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the "Stock Options"), in connection with his appointment to the Board of Directors pursuant to the Mateon Therapeutics, Inc. 2015 Equity Incentive Plan and the Amended and Restated Director Compensation Policy. The Stock Options will vest in three equal annual installments on the first, second and third anniversary of the date of grant, subject to Dr. Sandage's continued service on the Board of Directors as of such date. /s/ Megan N. Gates, attorney-in-fact 2016-10-27